Editas Medicine, Inc.

With $123.6M in cash and $17.3M in debt, EDIT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$73.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -326.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $19.7M (2022) to $40.5M (2025), reflecting a 106% increase over the period.

With a beta above 1.5, EDIT tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, EDIT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing EDIT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.